Crinetics Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Crinetics Pharmaceuticals, Inc. on January 20, 2026. The report discloses a change in the title and responsibilities of a senior executive officer, effective January 2, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Executive Title Change: Jeff Knight's title was changed from Chief Operating Officer to Chief Development and Operating Officer.
- Effective Date: The change in title and responsibilities is effective as of January 2, 2026.
- Compensation: There were no changes to Mr. Knight's compensation arrangements resulting from this title change.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No new risks, contingencies, or unusual items were disclosed in this report. The change in title is described as a reflection of Mr. Knight's existing responsibilities and scope of duties.
Investor Verification Checklist
- Verify the updated organizational chart to confirm the new reporting structure under the Chief Development and Operating Officer role.
- Review the 2025 Proxy Statement (filed April 23, 2025) for the full description of Mr. Knight's business experience and existing compensation terms.
- Confirm that no other undisclosed related party transactions or family relationships exist involving Mr. Knight, as stated in the filing.